Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 3/20 | 0.82 |
| ▸ | NPC1 | O15118 | 2/20 | 0.82 |
| ▸ | RAB9A | P51151 | 2/20 | 0.82 |
| ▸ | IGF2BP1 | Q9NZI8 | 2/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 1/20 | 0.82 |
| ▸ | STAT3 | P40763 | 1/20 | 0.82 |
| ▸ | HTT | P42858 | 1/20 | 0.82 |
| ▸ | ATM | Q13315 | 1/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | ACHE | P22303 | 2/20 | 0.56 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cucurbitacin A SCHEMBL22877913 | 1.00 | ITGAL (0.82) | ITGALNPC1RAB9AIGF2BP1SMN1; SMN2 | |
| Cucurbitacin A SCHEMBL22877821 | 1.00 | ITGAL (0.82) | ITGALNPC1RAB9AIGF2BP1SMN1; SMN2 | |
| Cucurbitacin A SCHEMBL20121493 | 1.00 | ITGAL (0.82) | ITGALNPC1RAB9AIGF2BP1SMN1; SMN2 | |
| Amarin SCHEMBL20121442 | 0.90 | ITGAL (1.00) | ITGALNPC1RAB9AIGF2BP1SMN1; SMN2 | |
| Amarin SCHEMBL18177462 | 0.90 | ITGAL (1.00) | ITGALNPC1RAB9AIGF2BP1SMN1; SMN2 | |
| Amarin SCHEMBL17531553 | 0.90 | ITGAL (1.00) | ITGALNPC1RAB9AIGF2BP1SMN1; SMN2 | |
| Amarin SCHEMBL22433345 | 0.90 | ITGAL (1.00) | ITGALNPC1RAB9AIGF2BP1SMN1; SMN2 | |
| Amarin SCHEMBL13668120 | 0.90 | ITGAL (1.00) | ITGALNPC1RAB9AIGF2BP1SMN1; SMN2 | |
| Amarin SCHEMBL19186443 | 0.90 | ITGAL (1.00) | ITGALNPC1RAB9AIGF2BP1SMN1; SMN2 | |
| Cucurbitacin B SCHEMBL29602393 | 0.90 | ITGAL (1.00) | ITGALNPC1RAB9AIGF2BP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12495802-B2 | Phagostimulant formulation for control of pest | R, Manoj Kumar (IN) | 2025-12-16 | — | — | US | claimed |
| WO-2023231582-A1 | PICRORHIZAE RHIZOMA CUCURBITANE SAPONIN EXTRACT AND USE THEREOF IN PREPARATION OF DRUG FOR TREATING CONSTIPATION | 山西省中医药研究院（山西省中医院） | 2023-12-07 | — | — | WO | claimed |
| WO-2023106777-A1 | VITAL MELON (KCTC14699BP) AND ANTI-OBESITY COMPOSITION COMPRISING EXTRACT THEREOF | 광동제약 주식회사 | 2023-06-15 | — | — | WO | claimed |
| US-20230044077-A1 | PHAGOSTIMULANT FORMULATION FOR CONTROL OF PEST | R, Manoj Kumar (IN) | 2023-02-09 | — | — | US | claimed |
| EP-4739098-A1 | METHODS OF PRODUCING NATURAL SWEETENERS | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) (IL) | 2026-05-13 | — | — | EP | disclosed |
| US-12509530-B2 | Single domain antibodies directed against intracellular antigens | Singh Moelcular Medicine, LLC (US) | 2025-12-30 | — | — | US | disclosed |
| US-12495802-B2 | Phagostimulant formulation for control of pest | R, Manoj Kumar (IN) | 2025-12-16 | — | — | US | disclosed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| CN-120241765-A | Composition containing cucurbitacin A and application thereof in preparation of anti-pancreatic cancer drugs | 杭州市第一人民医院(西湖大学附属杭州市第一人民医院) | 2025-07-04 | — | — | CN | disclosed |
| CN-120241765-A | Composition containing cucurbitacin A and application thereof in preparation of anti-pancreatic cancer drugs | 杭州市第一人民医院(西湖大学附属杭州市第一人民医院) | 2025-07-04 | — | — | CN | disclosed |
| CN-119842762-A | Epimerase Epi20 gene and application thereof in preparation of cucurbitacin | 云南农业大学 | 2025-04-18 | — | — | CN | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20150265555-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150265555-A1 | Chemosensory Receptor Ligand-Based Therapies | ANJI PHARMACEUTICALS INC. | 2015-09-24 | — | — | US | disclosed |
| US-9050292-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9050292-B2 | Chemosensory receptor ligand-based therapies | ELCELYX THERAPEUTICS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140030332-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140030332-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | ITGAL 810/4885NPC1 31/4885RAB9A 3961/4885 |
| US-12509530-B2 | Single domain antibodies directed against intracellular antigens | STAT3, STAT5B, STAT5A | ITGAL 2016/4885NPC1 3294/4885RAB9A 2963/4885 |
| US-20120177730-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | ITGAL 2328/4885NPC1 923/4885RAB9A 3767/4885 |
| US-20150265555-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | ITGAL 2328/4885NPC1 923/4885RAB9A 3767/4885 |
| US-20140030332-A1 | Chemosensory Receptor Ligand-Based Therapies | TAS1R2, TAS2R1, GPR119 | ITGAL 2328/4885NPC1 923/4885RAB9A 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.